Ion Channel Drug Discovery at Axxam

The webinar recording from the live session held on 28 April 2021 will be available to view until 31 December 2021

Despite the importance of ion channels and transporters in the pathogenesis of human diseases having been underlined for a long time, ion channel modulators account for only 2.8% of all FDA approved drugs. Nevertheless, the combination of recent technical electrophysiology breakthroughs, the ever-improving accuracy of genetic studies and the design of focused chemical libraries, has allowed the pharmaceutical community to tremendously increase ion channel research in the last decade.

During this webinar we will illustrate how Axxam can support your needs in ion channel drug discovery: from the generation and validation of a cellular assay, allowing the high-throughput screening of compounds, to the study of the mode of action of a selected molecule, using single channel recording on a cell or even a subcellular organelle.
Indeed, while the biophysical and pharmacological characterization of ion channels within the plasma membrane is extensively documented, its organellar counterparts, which contribute for more than 80% of the cellular electrogenic transport, is still largely understudied.

Ion channels; automated patch-clamp; organellar electrophysiology; drug discovery; high-throughput screening.


Jean-François Rolland, PhD
Head of Electrophysiology

Jean-François is the Head of Electrophysiology in Axxam. He has been “playing” with ion channels for more than 20 years, first in academia and since 2007 in the biotech world. After his PhD in Brussels and a post-doc in Italy he worked for four years at Xention, a Cambridge (UK) based ion channel company. At the end of 2011, he joined Axxam, where he established the laboratory of Automated Patch-clamp and spent the last 10 years exploring new targets, establishing and validating new assays.
Today he heads a group of highly skilled electrophysiologists in Axxam, who investigate and assess new druggable ion channels, perform biophysical and pharmacological validation and compound profiling. In particular, the group are pioneers in characterizing and offering reliable assays for some intracellular ion channels.